New HIV Frontier: The Fight to Access Long-Acting Prevention Drugs
RIO DE JANEIRO – News that an antiretroviral drug injected twice a year had prevented almost all HIV infection in trials electrified the HIV sector two years ago – but access to Gilead’s lenacapavir has been slow, particularly for countries in Latin America. Brazil, which faces significant HIV transmission in certain groups, has been routinely […]
We haven't written up this one. Health Policy Watch has the full story — the link below goes straight to it.
